GILD Gilead Sciences, Inc.

$GILD OCT30 160C · still actionable Zone: $152.00 to $154.14 Invalidation: close under $150 Objectives: $160.51, then $170 The math: up 4.9% to the first objective and 11.1% to the second, against 2.0% risk on the invalidation, better than 5 to 1 to the second Dear friend, picture a swing setup where a strong stock took a step back on Monday and landed on solid ground. Gilead closed at $153.07, down 2.0 percent on the day, after buyers held the $152.92 low well above the $150 round number, which means the pullback stopped where support should matter most. Earnings on October 29 give this move a clear test, and what that means for you is simple. If price can reclaim ground toward the $160.51 high from last week, the dip will look like rest rather than damage. P.S. Watch the $150 line on a closing basis. A close below it changes the whole story, and a hold above it keeps the path back to $160.51 open.

$GILD OCT30 160C · still actionable Zone: $152.19 to $154.33 Invalidation: close under $150 Objectives: $160.51, then $170 The math: up 4.7% to the first objective and 10.9% to the second, against 2.1% risk on the invalidation, better than 5 to 1 to the second Dear friend, picture a strong horse that stumbled on a wet patch and caught itself before it fell. Gilead closed at 156.51 dollars yesterday, dipped to 151.71 dollars this morning, and is holding near 153.26 dollars, and what that means is buyers stepped back in well above the 150 dollar line instead of letting the slide run. This is a swing setup into earnings on October 29, one day before these calls expire, so the report itself becomes the spark that can push price back toward its recent highs. P.S. Price touched 160.51 dollars on October 15, its highest level in a year, so the first objective is ground buyers have already proven they will pay for.

$GILD been with this since 2019. GILD does not have a strong consistent directional bias after earnings reports. My data shows it finishes higher a bit more than half the time on the next trading day, with average/median moves that are modestly positive but frequently small. Gilead was quite active this year with bigger deals aimed at long-term growth in oncology & inflammation unfortunately these create large near-term accounting charges that temporarily reduce reported profits, but we can view it as investments for future revenue. Arcellx (February 2026, completed April 2026) — ~$7.8 billion for the CAR-T company (partner on anito-cel for multiple myeloma). Ouro Medicines (March 2026, completed around June 2026) — up to ~$2.2 billion for a T-cell engager program in autoimmune diseases (structured with Galapagos/Lakefront involvement). Tubulis (April 2026, completed May 2026) — up to ~$5 billion ($3.15 billion upfront) for the German ADC biotech. Slow and steady is still the pace.

$GILD Unstoppable! This is running well! Now time to stack $ASMB for the buyout or massive boom in 2027!

$GILD gets an oral IL23 on the cheap, adding it alongside a4b7 in the IBD pipeline… …only one more piece to complete the armamentareum and all but guarantee *complete* dominance of the oral IBD market. Let’s see!

$GILD decade long base breakout and retest here in 2026. Seems so straight foward and simple this year doesn't it lol.

Gilead Sciences reported strong Q3 2026 results, beating expectations with adjusted EPS of $2.55 versus $2.17 estimated and revenue of $8.3B versus $7.79B, a more than 6% beat. The company raised its 2026 product sales guidance to $31.0B–$31.3B, with the $31.15B midpoint above Wall Street’s prior $30.77B consensus. CEO Daniel O’Day said the company delivered its strongest year-over-year base-business growth in more than a decade. The HIV franchise was the main growth driver, rising 18% year over year, while HIV prevention sales nearly doubled. Biktarvy generated $4.1B in revenue, up 10%, and injectable PrEP treatment Yeztugo continued expanding rapidly. Before earnings, Jefferies raised its price target to $185 and maintained a Buy rating. Shares had already reached a 52-week high of $165.70 during regular trading. $GILD

$GILD Gilead reports Q3 Thursday after the close. Zacks consensus sits at 2.16 dollars a share on 7.81 billion dollars of revenue, up just 0.6% from a year ago. That is basically flat vs Q2's actual 7.80 billion too, even though HIV sales grew 12% in Q2 to 5.69 billion and management raised full-year HIV growth guidance to 9% to 10%. Veklury getting guided down and cell therapy guided to a mid-teens decline are doing the offsetting. Yeztugo did 232 million dollars in Q2, up 40% sequentially, and management maintained a roughly 1 billion dollar full-year target for it. The ramp has to keep steepening from here.

$GILD the Arcellx deal has a sales hurdle tucked into Note 6 of the 10-Q. Former Arcellx holders only collect the contingent value right, 5 dollars a share or about 300 million dollars total, if anito-cel reaches at least 6 billion dollars in cumulative global sales from launch through the end of 2029. Same filing puts the anito-cel FDA decision date at Dec 23, 2026.

$GILD Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $2.55 up 3.24% YoY • Reported revenue of $8.3B up 6.83% YoY • For FY2026, Gilead raised product sales guidance to $31B, from $30.1B; product sales excluding Veklury are $30.7B, from $29.8B; diluted loss per share is now -$4.4 versus previously -$3.75.

$GILD Keeps pressing higher keep an eye on $ASMB I think that has a mega rip coming. Gilead is keen on their research.

$GILD OCT30 160C · update Called at $153.07 on Oct 20, now $157.19 (+2.7%). The trade is working, with objectives at $160.51, then $170, and the invalidation at $150. P.S. Watch the $160.51 level from here, since that first objective is the next real test of this move.

$GILD $VIR fair points. I have no interest in rebutting your every point. If you think the company is scamming you then you should sell now. I come to biotech investing knowing that treatment discovery is a long and winding road. The majority of treatments fail to meet endpoints and companies need to decide if continuing is wise. I don’t expect every drug candidates to become blockbuster drugs. I believe companies need to be transparent but I don’t share your view that everything is bad.

The daily tells you when. The weekly tells you if. $GILD held 2% above its July shelf during a -7.5% pullback and never reached the 30-week line — then new highs. $MU bounces keep failing inside a weekly that broke in June. Bigger chart always wins. Educational, not advice

$GILD - Stock consolidating on the weekly time frame and making cup shaped pattern. Swing calls added in the group. Looking for a bigger breakout above $155 for a move towards $165 and $180. high watch going into next few weeks. Recent news - Vir Biotechnology Announces Collaboration, License Agreement With Gilead To Discover, Engineer Three PRO-XTEN Dual-Masked T-Cell Engager Development Candidates Targeting Selected Solid Tumor-Associated Antigens

$GILD | Gilead Sciences Q3 Earnings: - Net Income: $2,429M - Product Sales: $8,289M - EPS: $1.94 - Adjusted EPS: $2.55 (est $2.19) - Sees FY Adjusted EPS: -$1.2 To -$0.85 - Sees FY Product Sales: $31,000M-$31,300M - FY GAAP And Adjusted Loss Per Share Outlook Includes Impact Of About $9.88 From Acquired $12.4B IPR&D Charges

GILEAD SCIENCES $GILD Q3 ADJUSTED EPS BEATS AT $2.55, FY OUTLOOK IS A LOSS ON ACQUIRED R&D CHARGES • Adj EPS: $2.55 vs $2.19 est, beat • Product sales: $8.289B • EPS: $1.94 • Net income: $2.429B FY outlook: • Product sales: $31B-$31.3B • Adj loss per share: $0.85-$1.20 • The loss outlook includes an impact of about $9.88 per share from $12.4B in acquired IPR&D charges

$GILD Great financial health, but very low growth and technology progression this year. It shall pull back.

$GILD Would love a drop here to 140-150, between the 100 day and 50 day would be a deal

$GILD reports earnings today after the close. I’m bullish heading into the report: GILD has beaten EPS estimates in 8 of its last 8 reports, according to Stock Meadow.